Dementia Discovery Fund Secures $269M in Second Fund to Accelerate Novel Therapeutics Development
Key Insights
The Dementia Discovery Fund (search) (DDF), managed by SV Health Investors (search), has closed its second fund with $269 million in commitments, bringing its total raised capital to over $550 million for dementia (search) therapeutics development.
The fund has secured backing from previous cornerstone investors including AARP (search), British Business Bank (search), Gates Frontier (search), pharmaceutical giants Bristol Myers Squibb (search), Eli Lilly, and Pfizer, with the Alzheimer's Association joining as a new investor.
DDF-2 has already invested in four companies and aims to build a portfolio of 10-15 innovative biotech ventures across the UK, Europe, and US, addressing the urgent global challenge of dementia (search) affecting over 50 million people worldwide.
SV Health Investors (search)' Dementia Discovery Fund (search) (DDF) announced the final closing of its second fund, DDF-2, securing $269 million in commitments to advance novel therapeutics for dementia (search). The closing, announced on May 20, 2025, establishes DDF as the world's largest specialized venture capital fund family focused exclusively on dementia treatment innovation.
With this latest fund, DDF has raised more than $550 million to date, reinforcing its commitment to addressing one of healthcare's most significant challenges. According to the World Health Organization, dementia (search) currently affects over 50 million people globally, with nearly 10 million new cases diagnosed annually.
Strategic Investment Focus
DDF-2 has already deployed capital to four companies, maintaining its investment strategy of building and backing highly innovative biotech ventures developing transformative therapies for patients worldwide. The fund aims to construct a portfolio of 10 to 15 companies, primarily across the UK, Europe, and the United States.
Kate Bingham, Managing Partner at SV Health Investors (search), emphasized the urgency behind the fund's mission: "As well as the unspeakable human cost, the economic burden of dementia (search) is entirely unsustainable. It is set to reach $3 trillion per year, greater than the entire pharmaceutical prescription drug market, yet our ability to treat patients is still extremely limited."
The fund has attracted support from its previous cornerstone investors, including AARP (search), British Business Bank (search), and Gates Frontier (search), alongside pharmaceutical companies Bristol Myers Squibb (search), Eli Lilly, and Pfizer. The Alzheimer's Association has joined as a new investor in this final close.
Building on Emerging Momentum
Jonathan Behr, Partner at SV Health Investors (search), noted the changing landscape in dementia (search) therapeutics: "Drug development for dementia is thankfully gaining momentum since the launch of DDF and the first disease-modifying Alzheimer's (search) drugs have been approved – underscoring that success is possible but that we still have far to go."
The fund's investments have already made a tangible impact on clinical research. Christian Jung, Partner at SV Health Investors (search), highlighted: "As a result of our investments, more than 2000 people have received experimental treatments, giving fresh hope to the mission to defeat dementia (search)."
Addressing a Global Health Priority
With no cure currently available for dementia (search), DDF's investment approach targets this vast unmet medical need through a science-first approach to investing in therapeutic assets and platform technologies. The fund aims to harness innovation similar to advances seen in cancer and other disease areas.
The economic impact of dementia (search) presents both a challenge and opportunity. The global cost of dementia care is projected to reach $3 trillion annually, exceeding the entire pharmaceutical prescription drug market. This economic burden underscores the potential value of effective therapeutics in this space.
DDF-2 will continue the fund's established strategy of identifying and supporting companies with promising approaches to dementia (search) treatment, while simultaneously working to generate attractive returns for investors. The fund represents a significant commitment to advancing the field of dementia therapeutics at a time when scientific understanding and treatment options are beginning to expand.